Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel

Table 4 Association of high-risk interactive genotypes with platelet aggregation and clinical outcomes

	patients carrying the high-risk interactive genotypes (n = 87)	patients carrying the low-risk interactive genotypes (n = 288)	p value
AA-induced platelet aggregation (%)
before clopidogrel	85.3 ± 14.8	71.2 ± 17.4	< 0.001
after 7–10 days clopidogrel	55.5 ± 12.6	35.3 ± 14.9	< 0.001
inhibition	30.2 ± 9.2	38.1 ± 11.4	< 0.001
ADP-inducedplatelet aggregation (%)
Before clopidogrel	79.1 ± 16.2	67.9 ± 14.8	< 0.001
after 7–10 days clopidogrel	45.2 ± 13.2	25.6 ± 8.6	< 0.001
inhibition	34.9 ± 12.3	46.4 ± 13.6	< 0.001
END (n, %)	34 (39.1)	61 (21.2)	< 0.001
RIS (n, %)	1 (1.1)	2 (0.7)	0.963
MI (n, %)	0 (0.0)	1 (0.3)	0.586
Death (n, %)	1 (1.1)	1 (0.3)	0.754
Safety outcomes
Asymptomatic HT (n, %)	1 (1.1)	6 (2.1)	0.438
Asymptomatic ICH (n, %)	1 (1.1)	1 (0.3)	0.754
Extracranial bleeding (n, %)	2 (2.3)	9 (3.1)	0.443

AA arachidonic acid, ADP adenosine diphosphate, END early neurological deterioration, MI myocardial infarction, RIS recurrent ischemic stroke, HT hemorrhagic transformation, ICH intracerebral hemorrhage

ISSN: 1471-2377